Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Ai‐Ping Zhou
Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
Oncologist
Cancer Research
Medicine
Oncology
Related publications
Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Pathology and Oncology Research
Medicine
Forensic Medicine
Pathology
Oncology
Cancer Research
Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma
Clinical Genitourinary Cancer
Oncology
Urology
Cost-Effectiveness Analysis of Sunitinib Versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore
International Journal of Technology Assessment in Health Care
Health Policy
Cost-Effectiveness and Cost-Utility Analysis of Sunitinib Versus Sorafenib and Bevacizumab + Interferon-Alfa as First-Line Treatment for Metastatic Renal Cell Carcinoma in Ecuador
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma
Therapeutic Advances in Urology
Urology
Hypertension as Predictor of Sunitinib Treatment Outcome in Metastatic Renal Cell Carcinoma
Acta Oncologica
Nuclear Medicine
Radiology
Hematology
Oncology
Medicine
Imaging
Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-Induced Hypertension in Metastatic Renal Cell Carcinoma
Clinical Genitourinary Cancer
Oncology
Urology
A Phase I/Ii Trial of BNC105P With Everolimus in Metastatic Renal Cell Carcinoma
Clinical Cancer Research
Cancer Research
Oncology
OA13.03 Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double-Blind Phase 2 Trial
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
